iOnctura BV, an Amsterdam, Netherlands-based clinical-stage biotech developing cancer therapies, raised €17.5M in funding.
EIC Accelerator provided the financing, which consisted of:
- a grant of EUR2.5M, and
- EUR15M of equity investment.
The company intends to use the funds to advance its clinical program for IOA-289, an autotaxin inhibitor for the treatment of cancer.
Led by CEO Catherine Pickering, iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. The company has progressed two therapeutic candidates into mid-stage clinical development:
- IOA-244, a highly selective allosteric inhibitor of PI3Kδ; and
- IOA-289, a highly-selective, non-competitive autotaxin (ATX) inhibitor.
On 8 December 2022, iOnctura announced the first patient was dosed in a Phase Ib clinical trial of IOA-289 in metastatic pancreatic cancer.
FinSMEs
21/12/2022